24th Annual International Congress on Hematologic Malignancies

Click here to register

On behalf of OncLive and Dr. Lonial of Winship Cancer Institute we would to invite you to participate in “Toxicity Management in Multiple Myeloma: An OncLive Scientific Interchange and Workshop”. This 3-hour meeting will be used to share your valuable insights, expert knowledge, and practical experience on management of toxicities associated with novel therapies in the treatment of multiple myeloma. OncLive will be providing a dinner and honorarium of $1,000 for participation.  Conference Location: Eden Roc Miami Beach 4525 Collins Avenue, Miami Beach, Fl, 33140. Event Timing: Friday, February 28, 2020, at               6:00 PM – 9:00 PM

Through our partnership with PER, FLASCO members can get 50% off registration, by using the coupon code FLASCO2020*!

Thursday, February 27, 2020 – Sunday, March 1, 2020
Eden Roc Miami Beach

4525 Collins Avenue
Miami Beach, Fl, 33140
Phone: 305-531-0000

Now in its 24th year, the annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma provides practitioners who manage hematologic malignancies with the practical tools to translate emerging data into the best therapy for their patients, to personalize care according to patient and tumor characteristics, and to apply novel treatment strategies to improve patient outcomes.

We are pleased to feature expanded coverage on chimeric antigen receptor (CAR) T cells and immunotherapy in 2020. First, a full afternoon session on Thursday, February 27, 2020, will be dedicated to addressing advances in CAR T-cell therapy for hematologic malignancies, as well as strategies to overcome treatment resistance. Next, sessions on Friday, Saturday, and Sunday will focus on methods to apply state-of-the-art treatment strategies in your clinical practice setting. This engaging and highly interactive meeting will provide ample opportunity for attendees to interact with internationally renowned experts in the management of leukemias, lymphomas, myeloma, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), and benign hematologic malignancies. Our faculty will distill practice-changing evidence and recommend how to put this information into clinical context, so that you may apply it to real-world patient-care scenarios. The discussion will also focus on how to proactively mitigate and manage treatment-related toxicities associated with new cellular therapies.

Interspersed throughout the meeting are sessions of Medical Crossfire®, a nationally recognized healthcare communication platform for debate, discussion, and peer exchange. These sessions will provide attendees with the opportunity to explore some of the most challenging clinical situations in the management of hematologic malignancies—treatment scenarios with multiple potential approaches.

This dynamic Congress will inspire participants to reflect on and share the new information they have learned, and to apply these new practices in the clinical setting, with the ultimate goal of improving patient outcomes.

To earn an additional 4.0 AMA PRA Category 1 Credits™, attend the CAR T Preconference Workshop.

Hot Topics for 2020

  • The potential for cell-based therapy to change treatment paradigms in hematologic malignancies
  • Best practices for patients with non-Hodgkin and Hodgkin lymphoma
  • Recent data on, and approval of, targeted agent-based therapies for patients with chronic lymphocytic leukemia
  • State-of-the-art approaches for patients with smoldering and symptomatic multiple myeloma
  • Incorporation of novel agents in treatment algorithms for patients with acute leukemias
  • Emerging agents for patients with MPNs
  • The role of assessment of measurable/minimal residual disease
  • How to navigate the value-based landscape of healthcare

Benefits of Attending

  • Stay up-to-date with emerging and recently approved agents and approaches for patients with hematologic malignancies
  • Learn about molecular profiling and other emerging techniques for risk assessment
  • Improve your competence in managing treatment-related adverse events
  • Network with your peers and internationally renowned experts in hematology/oncology

Acknowledgment of Commercial Support

This activity is supported by educational grants from Agios Pharmaceuticals, Inc.; AstraZeneca; BeiGene, Ltd.; Daiichi Sankyo, Inc.; Karyopharm; Pfizer; Seattle Genetics, Inc.; and Servier Pharmaceuticals, LLC.

Target Audience

This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies may also participate.

Program Co-Chairs

Andre H. Goy, MD
Andre H. Goy, MD
Chairman and Director
Chief, Division of Lymphoma
John Theurer Cancer Center
Chief Science Officer
Regional Cancer Care Associates
Lydia Pfund Chair for Lymphoma
Professor of Medicine
Georgetown University
Hackensack, NJ
Jorge E. Cortes, MD
Jorge E. Cortes, MD
Director, Georgia Cancer Center
Eminent Scholar, Georgia Research Alliance
Augusta University
Augusta, GA
Sagar Lonial, MD, FACP
Sagar Lonial, MD, FACP
Professor and Chair, Department of Hematology & Medical Oncology
Emory School of Medicine
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, GA


Click here to register